ClinicalTrials.gg
CompletedNCT06497972ABWEUpdated Aug 24, 2025

Blood Glucose Response of Novel Wild Rice Enhanced Food Products (Trial 1)

An interventional study of White bread (control, 32 grams, 14.4 grams of carbohydrate) and Brown rice cake in Blood Glucose, sponsored by Dylan MacKay. Completed at 1 site in Canada. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Dylan MacKay · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The goal of this acute double-blind cross over trial is to test the effects of a wild rice cake product compared to products currently on the market on glycaemic control. The main questions it aims to answer are:

  1. What is the effect compared to products currently on the market on glycaemic control?
  2. Is the wild rice product palatable?

Participants will:

  • consent to attend 4 study visits being 2.5 hours each
  • come to each visit fasted for at least 10-12 hours.
  • complete a Motivation to Eat VAS following each blood measure
Read the detailed description

This trial will be an acute double-blind cross-over trial and will investigate 2 types of rice cake products tested against a white bread control. This is the first of the two trials and will be assessing a wild rice cake and a brown rice cake against a control of white bread.

Participants will fast and arrive at the RCFTR between 7:00 and 11:00 am on the session day. They will be provided either of the study treatment based on randomization sequence. Baseline blood glucose (0 min) will be measured twice via finger stick blood sample right before their first bite of the study product, and at 15, 30, 45, 60, 90 and 120 mins after baseline in duplicate. The timer will be started when they take their first bite. VAS will be completed following consumption of the treatments to measure palatability.

The primary objective is to test the effects of a wild rice cake compared to products currently on the market by evaluating factors that influence glycemic response to wild rice in humans, performed via the finger stick blood glucose that will be measured throughout each session as outlined above.

02

Conditions studied

  • Blood Glucose

Keywords

  • glycemic response
  • glycemic control
  • rice
03

In context

Lead sponsor

Dylan MacKay is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing and able to give for participation in the trial
  • Male or female between 18-50 years old
  • range in between 18.9-29.9 kg/m2
  • Fasting glucose \<5.6 mmol/L
  • Usually eat breakfast
  • Participant must receive at least two doses of COVID-19 vaccine that have been recognized by Winnipeg Regional Health Authorities.
  • In the Investigator's opinion is able and willing to comply with all trial requirements

Exclusion criteria

Exclusion Criteria:

  • Fasting glucose ≥ 5.6 mmol/L or \<3.5 mmol/L
  • Female participant who is pregnant, lactating or planning pregnancy during the course of the trial
  • Participants who indicate that they could not finish study treatments within 10 minutes
  • Use of medication or supplements that may influence carbohydrate metabolism, including, not limit to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic within 4 weeks of screening visit
  • History of disordered eating, AIDS, hepatitis, a history of endocrine (including Type I and Type II diabetes mellitus), cardiovascular (including but not limit to atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, biliary or GI disorders
  • Intolerance or allergic reaction to rice
  • Existing restrictive dietary habits (such a vegan, low carbohydrate/keto) Date and version No: December 12 , 2022, Version 2 Page 7 of 15
  • History of hypertension
  • History of cancer within the last two years (except for non-melanoma skin cancer)
  • Recent history (within 12 month of screening) or current consumption of >14 drinks per week, (1 drink = 12oz of beer, 5oz of wine or 1.5oz distilled spirits)
  • Body weight change over 3.5kg for the past 3 months
  • Participants who have participated in another research trial involving an product in the past 12 weeks
  • Had significant physical trauma or major surgery in the past 3 month or had trauma or major surgery in the past 3 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
19 participants (actual)

Study arms

  • Active comparator
    Consumption of the control white bread product (32 grams, 14.4 grams of carbohydrate)

    Other: White bread (control, 32 grams, 14.4 grams of carbohydrate)

  • Experimental
    Consumption of brown rice cake 40 grams (31 grams of carbohydrate)

    Other: Brown rice cake

  • Experimental
    Consumption of wild rice brown rice blend cake 40 grams (31 grams of carbohydrate)

    Other: Wild rice (25%) and brown rice (75%) cake

  • Active comparator
    Consumption of the control white bread product (66 grams, 31 grams of carbohydrate)

    This arm was conducted after the first three arms in a non-randomized add on session as we identified an issue with the amount of carbohydrate in out comparator being half of what it was supposed to be. This arm provided 66 grams of white bread control product and there will be a minimum of three days separating each visit.

    Other: White bread (control, 66 grams, 31 grams of carbohydrate)

Interventions

  • OtherWhite bread (control, 32 grams, 14.4 grams of carbohydrate)

    32 grams of white bread, providing 14.4 grams of carbohydrate, which was incorrectly dosed and matched only half the carbohydrate in the rice cakes.

  • OtherBrown rice cake

    A 40g rice cake made of 100% brown rice (providing 31 grams of carbohydrate)

  • OtherWild rice (25%) and brown rice (75%) cake

    A 40g rice cake made of a blend of 25% wild rice and 75% brown rice (providing 31 grams of carbohydrate)

  • OtherWhite bread (control, 66 grams, 31 grams of carbohydrate)

    66 grams of white bread, providing 31 grams of carbohydrate, this arm was added after the mistake in the first control dosing was discovered, so this arm was not randomized and was completed after the first three.

06

What researchers measure

Primary outcomes

  1. The effects of different wild rice products compared to products currently on the market on glycaemic control.

    Finger stick blood glucose will be measured throughout each session.

    Time frame: Capillary blood glucose will be measured at 0 (baseline) and then 15, 30, 45, 60, 90 and 120 minutes after the first bite of treatment.

Secondary outcomes

  1. To measure the palatability of the wild rice products following consumption.

    Visual Analogue Scale (VAS).

    Time frame: VAS measuring palatability will be completed immediately after the consumption of the treatments.

07

Study locations

1 site
  • Chronic Disease Innovation Centre, Seven Oaks Hospital
    Winnipeg, Manitoba R2V 3M3, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Apr 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2024
First posted
Jul 12, 2024
StartActual
Jul 5, 2024
Primary completionActual
Apr 18, 2025
CompletionActual
Apr 18, 2025
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06497972
Lead sponsor
Dylan MacKay
Responsible party
Dylan MacKay (Assistant Professor, University of Manitoba) — Sponsor-investigator
First posted
Jul 12, 2024
Start date
Jul 5, 2024
Primary completion
Apr 18, 2025
Completion
Apr 18, 2025
Last update
Aug 24, 2025

Study contacts

Dylan MacKay, PHD
principal investigator · University of Manitoba

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion